Japan-based Sekisui Chemical has entered into an agreement with pharmaceutical firm Eisai to buy its subsidiary Eidia, which is involved in manufacturing, importing, and selling chemical equipment, clinical diagnostic reagents, clinical analysers ... Chemicals Technology, 1 day ago
BRIEF-Sekisui chemical says to buy eisai unit eidia ~ - Reuters UK, 4 days ago
Eisai Co Ltd:To sell 17,979,195 shares (100 pct stake) in Eisai's wholly owned Tokyo-based subsidiary EIDIA Co.,Ltd to Sekisui Chemical Co Ltd, at price of 22,450 mln yen in total, on Dec. 28.To cut stake in the subsidiary to 0 pct fromReuters UK, 4 days ago Notice of the Acquisition of Shares in the Clinical Diagnostic Reagents Company "EIDIA Co. Ltd." Noodls, 4 days ago
Morphotek Inc., a subsidiary of Eisai Inc., announced that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an ...PharmaBiz, 5 days ago Morphotek and Gothenburg University to develop farletuzumab for ovarian cancer Pharmaceutical Technology, 6 days ago Morphotek links with University of Gothenburg to develop farletuzumab17-11-2015 Pharma Letter, 1 week ago
Release date- 20112015 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that it has entered into an agreement to license its in-house discovered selective phosphodiesterase 4 (PDE4) inhibitor E6005 to Roivant ...4 Traders, 1 day ago Roivant Sciences gains global rights to Eisai's dermatitis candidate E6005 Pharma Letter, 1 day ago Eisai Licenses Selective Phosphodiesterase 4 Inhibitor E6005 To Roivant Sciences FirstWord Pharma, 4 days ago US district court upholds Helsinn's patent on antiemetic agent Aloxi PharmaBiz, 6 days ago
Eisai inks joint research pacts with University of Liverpool & MMV to develop new antimalarial medicines
Eisai Co., Ltd. has entered into two joint research agreements for the development of new antimalarial medicines. The first of these agreements is a joint development programme with the Liverpool School of Tropical Medicine, Liverpool, UK and the ...PharmaBiz, 2 weeks ago Eisai forms joint antimalarial medicine research programmes Manufacturing Chemist, 2 weeks ago
Eisai inks research pact with Paoli Calmettes Institute to identify compounds for biological evaluation in oncology indications
Eisai Inc., the US pharmaceutical subsidiary of Eisai Co., Ltd., has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC), a private non-profit comprehensive cancer centre in Marseille, France, ...PharmaBiz, 2 weeks ago Eisai Signs Research Collaboration Agreement with the Paoli Calmettes Institute Ulitzer, 2 weeks ago Eisai Inc. Signs Research Collaboration Agreement With BioSpace, 2 weeks ago
/PRNewswire/ -- PRESSEMITTEILUNG NUR FÜR DEUTSCHE MEDIEN Eisai kündigt heute eine Änderung des Zugangs zu Fycompa ® (Perampanel) in Deutschland an. Ab dem 1 . April 2016 erfolgt die Lieferung von Perampanel über etablierte ...PR Newswire, 2 weeks ago
Morphotek Inc Announces Initiation Of Amatuximab Study In FirstLine Unresectable Malignant Pleural Mesothelioma Patients
Wednesday, November 18, 2015 EXTON, Pa. , Nov. 18, 2015 /PRNewswire/ -- Morphotek ® , Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS— A matuximab R esearch in T ...Pharma Focus Asia, 5 days ago Morphotek??, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients Tutorial Finder, 6 days ago Morphotek®, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients Fat Pitch Financials, 6 days ago Morphotek Announces Collaboration Agreement With University of Gothenburg To Develop Farletuzumab, An Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, For Alpha-Particle Radioimmunother Freshnews.com, 1 week ago
Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® netupitant/palonosetron in American Society of Clinical Oncology ASCO Antiemetics...
Helsinn Group and Eisai Inc. Announce Inclusion of AKYNZEO® netupitant/palonosetron in American Society of Clinical Oncology ASCO Antiemetics Guideline Update By a News Reporter-Staff News Editor at Biotech Week -- Helsinn Group and Eisai Inc.4 Traders, 5 days ago Helsinn and Eisai's Akynzeo included in ASCO antimetics guideline update Pharma Letter, 1 week ago Helsinn and Eisai Announce Inclusion of AKYNZEO (netupitant/palonosetron) in American Society of Clinical Oncology (ASCO) Antiemetics Guideline Update FirstWord Pharma, 1 week ago
on your WebpageAdd Widget >Get your members hooked!